Psychotropic Drug Induced Metabolic Disorders
|
|
- Eustace Bradley
- 8 years ago
- Views:
Transcription
1 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 APRIL 2007 Review Article Psychotropic Drug Induced Metabolic Disorders J.K. Trivedi, Kumar Gaurav Department of Psychiatry, K.G. Medical University, Lucknow Abstract According to a report from the Centers for Disease Control and Prevention released in April, the leading cause of death contibuting to that shortened lifespan is not the patients mental illness, but rather something largely preventable cardiovascular disease. Metabolic disorders are known complications of newer antipsychotics. The term Metabolic Syndrome refers to a syndrome consisting of central obesity as indicated by excessive visceral fat, plasma lipid abnormalities, glucose dysregulation, and high blood pressure. The metabolic syndrome develops gradually, different drugs have differential propensity to cause it. This is a dreadful condition as it induces medical morbidities, which may be life threatening in patients. The criteria for diagnosing the metabolic syndrome propsed by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) are the most current and widely used but are not universally accepted. Common manifestations are dyslipidemia, hypertension, weight gain, increase in blood glucose etc. This review covers the latest available information on the drug induced metabolic syndrome. Risk factors and mechanisms are discussed. Introduction Patients with schizophrenia and bipolar disorder lose as much as 20 years off their average life expectancy compared with similar individuals in the general population without serious mental illness. According to a report from the Centers for Disease Control and Prevention released in April, the leading cause of death contibuting to that shortened lifespan is not the patients mental illness, but rather something largely preventable cardiovascular disease. These statistics and others were cited by an expert panel as indirect evidence that the filed of psychiatry is earning a failing grade when it comes to managing comorbidity in patients with schizophrenia and bipolar disorder especially those patients who are taking second generation antipsychotics (SGAs). This class of drugs is generally considered to be linked closely with increased risk of metabolic syndrome, a leading risk factor for cardiovascular disease. 1-5 Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation is patients treated with secondgeneration (or atypical) antipsychotics have raised concerns about a possible association between these metabolic effects and tr eatment with these medications. 5-6 Second generation antipsychotics (SGA) have demonstrated sever al advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metablic disorders, such as obesity, diabetes, and hyperlipidemia. 7 Substantial evidence from a variety of human populations, including some recent confirmatory 32 Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society
2 APRIL 2007 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 evidence in treated psychiatric patients, indicates that increased adiposity is associated with a variety of adverse physiological effects, including decreases in insulin sensitivity and changes in plasma glucose and lipid levels What is Metabolic Syndrome? The term Metabolic Syndrome refers to a syndrome consisting of central obesity as indicated by excessive visceral fat, plasma lipid abnormalities, glucose dysregulation, and high blood pressure. The criteria for diagnosing the metabolic syndrome propsed by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) are the most current and widely used but are not universally accepted. NCEP ATP III/WHO defines metabolic syndrome as: Obesity: High waist circumference BMI > 30 Dyslipidemia Hypertension High fasting glucose (> 110mg/dL) Expert panel on detection, evaluation and treatment of high blood cholesterol recommends the usage of the term metabolic syndrome if any three of the following five criteria are fulfilled. Obesity (Waist > 40 in men and 35 in women) High density lipoprotein cholesterol < 40 mg/ dl in men and < 50 mg/dl in women Triglycerides > = 150 mg/dl Blood pressure > 130 mm Hg systolic or 85 mmhg diastolic Fasting blood glucose >= 110 mg/dl A Prothombotic State with Elevated plasminogen activator inhibitor -1(PAI-1) AND A Proinflammatory State with increased C-reactive protein (CRP) are other features of metabolic syndrome. The metabolic syndrome has become increasingly common in the United States and other developed countries due to diet and limited exercise. It is estimated that about percent of US adults have it. Risks of Metabolic Syndrome Most mass index defined as the ratio between body weight in kilograms to the square of height in metres. (Weight in kg)/(height in meters) 2 < 17.5 Very Underweight > 20 (or 18.5) < 25 Normal > 25 Overweight or more > 30 Obese > 35 Morbidity obese Schizophrenics A Vulnerable Population Schizophrenics are a vulnerable population for metabolic syndrome because of the following factors: Smoking Obesity Diet higher in fat lower in fiber Sedentary lifestyle Increased prevalnce of diabetes Proneness to central obesity 4 Atypical Antipsychotics and Metabolic Syndrome Atypical antipsychotics cause : Weight gain Insulin resistance-diabetes Worsening lipid profile which predispose to metablic syndrome ADA* Consensus on Antipsychotic Drugs and Obesity and Diabetes Drug Weight Gain Diabetes Risk Dyslipidemia Clozapine Olanzapine Risperidone + + D D Quetiapine + + D D Aripirazole + Ziprasidone + Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society 33
3 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 APRIL 2007 ADA* Consensus on Antipsychotic Drugs and Obesity and Diabetes: Monitoring Protocol Start 4 wks 8 wks 12 wks Quarterly 12 mths 5yrs Personal /family X X history Weight BMI X X X X X Waist circumference X X Blood Pressure X X X Fasting Glucose X X X Fasting lipid profile X X X X * American Diabetologists Association. According to the protocol more frequent assessments may be warranted based on clinical status. Obesity as a risk factor for antipsychotic noncompliance Studies have shown that greater the BMI greater is the risk for non-compliance for antipsychotic drugs. Possible Mechanisms Behind Weight Gain with Olanzapine Weight gain due to Olanzapine may be explained by the following mechanisms: Improved functioning-less self neglect, improved eating habits Increase in appetite-carbohydrate craving, sedation and decreased motor activity Altered adipose tissue-metabolism, fat composition and distribution Effect on neurotransmitters - 5HT, H1, DA, Alpha 1 blockade Increase in leptin and prolactin levels Role of Receptors in Appetite and Weight gain Receptors have been found to play an important part in regulating appetite and weight gain. The following receptors are involved: Decreased 5HT action-increased eating Noncomplaint Respondents According to BMI Category *P = 0.01 vs normal; Chi-square: P = 0.03; Test for linearity: P = 0.01 Schizophrenia population 34 Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society
4 APRIL 2007 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 Decreased H1 action-increased eating Beta 3 adr energic-regulates energy metabolism and thermogenesis Leptin secreted by white adipose cells correlates highly with body fat mass. It also regulates insulin secretion and energy metabolism. Relationship between weight gain and base line BMI Some studies showed an inverse relationship between weight gain and baseline BMI. Whereas others gave contrary findings. Buckley et al reported that there was no significant association between body weight gain, changes in serum glucose level, Olanzapine dosage after three years study. 14 Medical Comorbidities with Bipolar Disorder Cardiovascular disease Relative cardiovascular mortality in male inpatients with bipolar disorder = 1.87 Obesity Central obesity is more common, especially with patients on antipsychotics Diabetes Prevalence = 9.9%; expected frequency = 3.4% Neurological disorders Migraine: prevalence = 25% of men, 27% of women; rate in men is almost 5x general population Atypical 52-Week Weight Gain Mean Change from Baseline Weight Effect of Antipsychotics on Glucose and Lipid Metabolism Clozapine Increased risk of diabetes, Risk of LDL, HDL and Olanzapine and reports of diabetic KA triglycerides Risperidone Discrepant results Risk of dyslipidemia is Quetiapine regarding risk of diabetes intermediate Ziprasidone Aripiprazole No apparent increase in risk, though these agents were released more recently ( versus Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society 35
5 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 APRIL 2007 Chronic pain syndromes Correlates of Obesity in Patients with Bipolar Disorder Male Hypertension Arthritis Diabetes mellitus > 4 manic episode > 1 suicide attempt Exposure to > 1 weight-increasing psychotropic Limited occupational functioning Comorbid binge-eating disorder Risk for Hyperlipidemia There is accumulating empirical evidence and growing clinical concern that some of the newer antipsychotic medications may increase the risk of hyperlipidemia. Case reports have linked treatment with clozapine and olanzapine to hyperlipidemia that disappears when antipsychotic medications are discontinued. Medical record reviews further support a connection between clozapine and olanzapine and the increased risk of hypertriglyceridemia. Prospective resear ch fur ther suggests that antipsychotic medications may adversely affect serum lipids. 15 High Low-potency Typical antipsychotics Olanzapine Clozapine Low High-potency Typical antipsychotics Risperidone Ziprasidone Aripiprazole Mechanisms for Dyslipidemia with Antipsychotics Greatest effect is on triglycerides, with acute severe hypertriglyceridemia sometimes reported. Obesity/Excess caloric intake. Not a high association between weight gain and increases in serum trigycerides. Insulin resistance, diabetes. H1 Antagonism (increased appetite) Association between high affinity for the H1 receptor and weight gain. 5-HT2c antagonism Poor correlation; high affinity for ziprasidone which is weight and triglyceride neutral. Prevalence of Diabetes and Impaired Glucose Tolerance are Relatively High in Schizophrenia and Bipolar Disorder Rates of type II diabetes mellitus in schizophrenia reportedly are 2-4 times the general population. The association between antipsychotic medication treatment and hyperglycemia has been reported since the 1950s. There are many complex mechanisms involved that leads to glycemic dyscontrol including receptor involvement. The Receptor Density following diagram shows the receptor density in insulin resistant cell and schizophrenics have got insulin resistance Parameters Monitored in Patients on Atypicals Personal and family history of diabetes and cardiovascular disease (obesity, dyslipidemia, hypertention) BMI (weight and height) Waist circumference Blood pressure 36 Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society
6 APRIL 2007 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 Fasting plasma glucose Fasting lipid profile In addition Patients with diabetes are monitored for glucose control; those with risk factors (obesity, family history of diabetes) are monitored for fasting glucose at baseline and periodically. Patients who develop polydipsia, polyuria, polyphagia, and weakness should also be monitored regularly. 20 Class Warning of Atypicals Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. The confounders are DM in schizophrenia, increasing incidence in population. Studies suggest an increased risk (of hyperglycemia related events) in patients treated with atypicals. But the precise relationship is not yet completely understood. The precise estimates for increased risk) are not available. Metabolic Dysregulation in Depression Depression is a risk factor for stroke and coronary artery disease independent of age, gender and lifestyle. The likelihood of developing myocardial infarction in depressed patients is four times that of the general population. The likelihood of stroke in depressed patients is 2.6 times that of the general population. Increased platelet activation, endothelial dysfunction, elevated inflammation markers and deficiencies in omega-3 fatty acids are supposed to contribute to the increased risk. Studies revealed that depressed subjects are 2.2 times as likely as depressed patients to develop diabetes. Depression impedes diabetes outcome by impeding functional impairment, decreasing glycemic control and increasing vascular complications. Weight Gain Associated with Tricyclic Antidepressants It is probably related to H1 antagonism. Tertriary amine TCA s are more potent H1 blockers and cause more weight gain. Weight Gain Associated with SSRI s Patients on SSRI s may have initial weight loss followed by weight gain. Down regulation of the 5HT2c receptor may be the cause of weight gain Weight Gain Associated with Antidepressants Common Often Occasional Rare or Never TCAs: Amitriptyline, Doxepin, Imipramine Mirtazapine TCAs: Desipramine, Nortriptyline SSRI: Paroxetine MAOI: Phenelzine Other SSRIs SNRIs MAOI: Tranylcypromine Nefazodone Weight Gain Associated with Mood Stabilizers Common Often Occasional Rare or never Weight loss Valproate Lithium carbonate Carbamazepine Lamotrigine Topiramate associated with SSRI s. As SSRI s are commonly prescribed a potentially large population may be experiencing the weight gain associated. Paroxetine is more likely than other SSRIs to be associated with weight gain. Other SSRIs appear largely similar, but head-to head comparisons are unusual. Weight Gain in Psychiatric Patients Clozapine and Olanzapine treatment are associated with the greatest risk of clinically significant weight gain, with other agents producing relatively lower levels of risk. Weight gain may be due to restoration of weight loss that might have occurred due to illness or due to dieting. Hypothyroidism might present a similar picture. Significant changes in lifestyle and medication-induced side effects may also cause weight gain. Careful history helps in identifying the cause of weight gain. Patients may be unaware of the cause of their weight gain as often there is no noticeable increase in appetite. Patients tend to blame themselves for overeating even when weight gain (and appetite) is drug-induced. 12,21 Conclusion Persons with high mental distress have a high prevalence of health risk behaviours. They are probably not getting optimal care for their medical conditions. The burden of their medical conditions Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society 37
7 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 APRIL 2007 must impede their full r ecovery from their psychiatric illness. Health Outcomes are not part of recovery goals or mental health system design. Mental health service systems should assess and respond to health risks by Screening and organizing programs to address smoking, obesity, lack of exercise Screening for diabetes, hypertension, metabolic syndrome Integrating client specific health information into psychotropic medication decision making Making improvement of physical health as a part of mental health activities References 1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salomen JT. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002; 288 : Mc Evoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80 : Marc A., De Hert. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Res 2006; 83(1) : Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006; 24 : M De Hert, R van Winkel, D Van Eyck, L Hanssens, M Wampers, A Scheen, and J Peuskens. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006; 2 : Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (suppl 1) : Ilaria Tarricone, Michela Casoria: Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health center. BMC Psychiatry. 2006; 6 : Remington G. Schizophrenia, Antipsychotics, and the Metabolic Syndrome: Is there a Silver Lining? American Journal of Psychiatry 2006; 163 : Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J: Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64 : Mark Olfson. Hyperlipidemia following treatment with antipsychotic medications. American Psychiatry. 2006; 163 : Brown S, Inskip H, Barraclough B. Causes of the excess mortality of Schizophrenia. Br J Psychiatry 2000; 177 : Jim Rosack. Clinicians Urged to Better Monitor Drug-Related side effects Psychiatr News 2006; 41 (31). 13. Ya Mei Bai, Chao-Cheng Lin et al: Association of Initial Antipsychotic Response to Clozapine and Long-Term Weight Gain. American Journal of Psychiatry. 2006; 163 : Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79 : Wayne S. Fenton, and Mark R. Chavez. Medication-Induced Weight Gain and Dyslipidemia in Patients with Schizophrenia. American Journal of Psychiatry. 2006; 163 : Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH: Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004; 65 : Kohen D: Diabetes mellitus and Schizophrenia: historical perspective. Br J Psychiatry 2004; 184 (suppl 47) : S64-S Cohn TA, Wolever T, Bois D, Zipursky RB, 38 Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society
8 APRIL 2007 DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 Remington G: First episode and neuroleptic free patients with schizophrenia have reduced insulin sensitivity: a minimal model analysis. Schizophr Bull 2005; 31 : Zhong Zhao. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophrenia Research 2006; 84(1) : David Straker, Christoph U. Correl. Cost- Effective Screening for the Metabolic Syndrome in Patients Treated with Second Generation Antipsychotic Medications. Am J Psychiatry 2005; 162 : Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (suppl 7) : Delhi Psychiatry Journal 2007; 10:(1) Delhi Psychiatric Society 39
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationDet metaboliske Syndrom Hvad er risikoen hos patienter? Hvad gør NIP skizofreni på området?
Det metaboliske Syndrom Hvad er risikoen hos patienter? Hvad gør NIP skizofreni på området? Henrik Lublin Centerchef, dr.med. Psykiatrisk Center Glostrup Increased Mortality Rates for Medical Disorders
More informationHEDIS CY2012 New Measures
HEDIS CY2012 New Measures TECHNICAL CONSIDERATIONS FOR NEW MEASURES The NCQA Committee on Performance Measurement (CPM) approved five new measures for HEDIS 2013 (CY2012). These measures provide feasible
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationMETABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS
METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS Andrew M. Cislo, PhD Megan J. Ehret, PharmD, MS, BCPP Robert L. Trestman, MD, PhD Kirsten Shea, MBA www.uchc.edu Background Metabolic
More informationPrevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder *
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder * Ruud van Winkel a, Marc De Hert a, Dominique Van Eyck a, Linda Hanssens b, Martien Wampers a, Andre Scheen
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationAtypical antipsychotics and the metabolic syndrome. Thomas R. Dekoj, MS3 UIC College of Medicine
Atypical antipsychotics and the metabolic syndrome Thomas R. Dekoj, MS3 UIC College of Medicine Antipsychotic uses Schizophrenia and related d/o ~1% Bipolar ~2% used widely in schizophrenia spectrum d/o,
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationMedications for bipolar disorder
Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationHow To Safely Use Aripiprazole
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice, variations
More informationBelow, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.
[Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationDiabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationMarc De Hert, M.D. Ph.D., Professor Psychiatry, UPC KU Leuven, Campus Kortenberg, Leuvense Steenweg 517, B-3070 Kortenberg, Belgium
METABOLIC SYNDROME IN PEOPLE WITH SEVERE MENTAL ILLNESS Introduction Marc De Hert, M.D. Ph.D., Professor Psychiatry, UPC KU Leuven, Campus Kortenberg, Leuvense Steenweg 517, B-3070 Kortenberg, Belgium
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationCardiovascular disease and diabetes in people with severe mental illness: causes, consequences and pragmatic management
Cardiovascular disease and diabetes in people with severe mental illness: causes, consequences and pragmatic management Richard IG Holt Human Development and Health Academic Unit, Faculty of Medicine,
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationTrends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)
Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known
More informationAntiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study
Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationThe Treatment of Patients with Bipolar l Disorder and its effects on diabetes
The Treatment of Patients with Bipolar l Disorder and its effects on diabetes By Lyndi Wiltshire Birmingham & Solihull Mental Health Foundation Trust Disclosures I provided paid educational sessions and
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More informationCardiovascular Disease Risk Factors
Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationModal subcomponents of metabolic syndrome in patients with bipolar disorder
Journal of Affective Disorders 106 (2008) 91 97 www.elsevier.com/locate/jad Research report Modal subcomponents of metabolic syndrome in patients with bipolar disorder Jeffrey Cardenas a, Mark A. Frye
More informationUpdate on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationMajor Depressive Disorder:
Major Depressive Disorder: An Actuarial Commercial Claim Data Analysis July 2013 Prepared by: Milliman, Inc. NY Kate Fitch RN, MEd Kosuke Iwasaki FIAJ, MAAA, MBA This report was commissioned by Takeda
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationDiabetes prevalence estimates in schizophrenia and risk factor assessment
Annals of Clinical Psychiatry Annals of Clinical Psychiatry 2011;23(2):117-124 Research Article Diabetes prevalence estimates in schizophrenia and risk factor assessment Tami Argo, PharmD, MS, BCPP Iowa
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationWHAT DOES DYSMETABOLIC SYNDROME MEAN?
! WHAT DOES DYSMETABOLIC SYNDROME MEAN? Dysmetabolic syndrome (also referred to as syndrome X, insulin resistance syndrome, and metabolic syndrome ) is a condition in which a group of risk factors for
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationAntipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Patient Tool #1 Understanding Diabetes and Psychiatric Illness: A Guide for Individuals, Families, and Caregivers Type 2 Diabetes,
More informationCHEM 1406 BSA/BMI Measurement Laboratory (revised 01/03//06) BSA, Body Surface Area
CHEM 1406 BSA/BMI (revised 01/03//06) BSA, Body Surface Area See pages 105-110 of dosage text for equations, calculations and adult nomogram See pages 270-273 of dosage calculation text for pediatric nomogram
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationUNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY. Dr Sanil Rege MBBS, MRCPsych, FRANZCP Director of CTF Training Course
UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Director of CTF Training Course Talks Director of the CTF Training course Overview of the metabolic syndrome
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationSerious Mental Illness: Symptoms, Treatment and Causes of Relapse
Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Bipolar Disorder, Schizophrenia and Schizoaffective Disorder Symptoms and Prevalence of Bipolar Disorder Bipolar disorder, formerly known
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationThe Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults
The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults Seán R. Millar, Jennifer M. O Connor, Claire M. Buckley, Patricia M. Kearney, Ivan J. Perry Email:
More informationSection 2. Overview of Obesity, Weight Loss, and Bariatric Surgery
Section 2 Overview of Obesity, Weight Loss, and Bariatric Surgery What is Weight Loss? How does surgery help with weight loss? Short term versus long term weight loss? Conditions Improved with Weight Loss
More informationDisability Evaluation Under Social Security
Disability Evaluation Under Social Security Revised Medical Criteria for Evaluating Endocrine Disorders Effective June 7, 2011 Why a Revision? Social Security revisions reflect: SSA s adjudicative experience.
More information1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More informationBIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS
BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical
More informationMetabolic issues and cardiovascular disease in patients with psychiatric disorders
The American Journal of Medicine (2005) Vol 118, Suppl 2, 15S 22S Metabolic issues and cardiovascular disease in patients with psychiatric disorders Daniel E. Casey, MD From the Department of Psychiatry,
More informationThe Health Status of the United States Workforce
P F I Z E R F A C T S Updated 2007 The Health Status of the United States Workforce Findings from the National Health and Nutrition Examination Survey (NHANES) 1999-2002, and the National Health Interview
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationAn Overview and Guide to Healthy Living with Type 2 Diabetes
MEETING YOUR GOALS An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS This brochure was designed to help you understand the health goals to live a healthy lifestyle with type
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationA starting point for today 30/04/2015. Obesity does matter. Obesity is modifiable. Reducing weight has demonstrable health benefit
Obesity Intervention for Front-Line Healthcare Providers Welcome to our MBTelehealth sites! A special evaluation plan for the day Linking Learning to Practice for FPs: Earn 2 Mainpro-C and 2 bonus Mainpro
More information28 Year-old Male w/uncontrolled Type 2 Diabetes, Bipolar Disorder Presents with Epigastric Pain. Jess Hwang 9/27/12
28 Year-old Male w/uncontrolled Type 2 Diabetes, Bipolar Disorder Presents with Epigastric Pain Jess Hwang 9/27/12 HPI Presented to an OSH with epigastric pain, diarrhea. + fevers up to 104.9 1 year ago
More informationDIABETES YOUR GUIDE TO
YOUR GUIDE TO DIABETES b What is diabetes? b Type 2 diabetes prevention b Prevention checklist b Living with diabetes b Complications b Terms to know b Resources To promote and protect the health of Canadians
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationThe Influence of Infant Health on Adult Chronic Disease
The Influence of Infant Health on Adult Chronic Disease Womb to Tomb Dr Clare MacVicar Introduction Many diseases in adulthood are related to growth patterns during early life Maternal nutrition important
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationDisclosures Christer Allgulander
How Patients With Generalized Anxiety Disorder (GAD) Are Treated in Specialized Care: A Pharmacoepidemiological Case Register Study in Sweden Christer Allgulander MD, Karolinska Institutet, Sweden Jan
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationAdminister a quarter of usual dose Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose Strong CYP2D6 and CYP3A4 inhibitors
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY ABILIFY (aripiprazole)
More informationCLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More informationA BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES
INTRODUCTION A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications.
More information